Michael Jandernoa

Michael Jandernoa has served on Cirius’ board of directors since May 2016. From January 1981 to February 2017, Mr. Jandernoa served as a director of Perrigo Company plc and its predecessor, Perrigo Company, a global healthcare supplier that develops, manufactures, and distributes over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients and consumer products. Mr. Jandernoa served as Perrigo Company’s chief executive officer from 1988 to 2000 and as chairman of the board of directors from 1991 to 2003. Mr. Jandernoa is a general partner of 42 North Partners, a member of the board of directors of Hopen Life Science Fund and a member of the board of managers of Metabolic Solutions Development Company, LLC. Mr. Jandernoa received his B.A. degree in business administration from the University of Michigan.